Indian Clinicians' Experiences with Montelukast-Levocetirizine for Allergic Rhinitis and Asthma: A Survey.

2025, Volume 1, Issue 1, Page 29-35

Dr. Ambika Singh Associate Professor, Department of ENT, Katuri Medical College & Hospital, Andhra Pradesh.

ijgpr 5.pdf

Download PDF • 574KB

Abstract

Background: Allergic rhinitis (AR) poses a substantial public health challenge in India. This study investigated Indian clinicians' perspectives on the use of montelukast and levocetirizine combination therapy for AR, particularly in patients with comorbid asthma. Materials and Methods: A cross-sectional survey was conducted among 882 Indian clinicians using a 27-item questionnaire assessing their clinical experiences with montelukast and levocetirizine in AR management. Data were analyzed using descriptive statistics, and results were presented as percentages and visualized using charts. Results: A significant proportion (64%) of clinicians recognized recurrent upper respiratory tract infections (URTIs) as a potential indicator of undiagnosed AR. The majority (81.63%) preferred antihistamine-leukotriene receptor antagonist (LTRA) combinations for long-term AR management, with levocetirizine being the preferred antihistamine (90.48%). Clinicians reported similar AR diagnosis rates across genders (80%) and observed morning symptom exacerbation in most patients (90.93%). The montelukast-levocetirizine combination was favored for its improved patient compliance (72%) and was frequently used in asthma patients before initiating inhalation therapy (77%). Conclusion: This survey reveals a strong preference among Indian clinicians for montelukast and levocetirizine combination therapy in AR management due to its efficacy and enhanced patient compliance. Recurrent URTIs were identified as a potential marker for undiagnosed AR, and the frequent co-occurrence of asthma and allergic conjunctivitis was noted.

Keywords: Allergic rhinitis, Montelukast, Levocetirizine, Leukotriene receptor antagonists, Asthma, India.